Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.08 USD | +3.64% | +5.38% | +65.68% |
May. 10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
May. 09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.68% | 1.63B | |
+52.26% | 55.7B | |
+41.08% | 39.91B | |
-5.51% | 39.57B | |
-5.56% | 28.16B | |
+15.71% | 26.3B | |
-21.17% | 18.94B | |
+33.10% | 12.17B | |
+26.22% | 12.12B | |
+2.11% | 12.12B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Wedbush Lowers Edgewise Therapeutics' PT to $23 From $27, Sees 2024 as 'Critical' Year; Keeps Outperform Rating